Rigel Pharmaceuticals

NCT00115089

7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic Rhinitis

NCT00326339

Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)

NCT00706342

Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)

NCT00665626

Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)

NCT00665925

Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis

NCT00752999

Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus

NCT00798096

Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma

NCT01591044

A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma

NCT01597050

Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions

NCT01900249

To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca

NCT02040623

Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)

NCT02112838

Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy

NCT02433236

Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy

NCT02612558

A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)

NCT04543279

Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia

NCT05040698

Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa

NCT05848258

An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

NCT06566742

A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.

NCT06597734

A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm

NCT06161974

Study of Olutasidenib and Temozolomide in HGG

NCT07032727

Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

NCT06782542

Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy

NCT06564207

Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Adults